Note s4
121 subscribers
329 photos
69 files
77 links
Download Telegram
๐Ÿ”ดMost common side effects of ARNI......
Angioedema
ูˆุงู„ุจู‚ูŠู‡ ู…ูˆุฌูˆุฏุงุช ุจ ู…ุญุงุถุฑุฉ
๐ŸŸค๐ŸŸคูƒู„ ู…ุฑุถู‰ ุงู„ูŠ ุนุฏู‡ู… stable ูˆู„ูŠุณ acute ุงูˆ unstabl ุงู†ุชุจู‡ ุฎุงู ูŠุฌูŠูƒ ูƒูŠุณ ูŽูŠูƒู„ูƒ unstabl ุฃูˆ acute ุฐุงูƒ ู…ูˆุถูˆุน ู†ุงุฎุฐู‡ ู„ูˆุญุฏู‡
ู‡ุณู‡ ู‡ู†ุง ูู‚ุท ู…ุฑูŠุถ
Stabl with HFrEF
ู‡ุฐุง ู†ุณุชุฎุฏู… ุฅู„ู‡ B.blocker
ุญุชู‰ ุฅุฐุง ู…ุฑูŠุถ ุฃุนุฑุถ ุฎููŠูู‡ ู†ุจุฏู‰ B. Blocker
ูˆู„ุง ุชู†ุณุง ู†ุจุฏู‰ ุจ B.blocker ู…ู† ูƒู„ุงุณ B.
๐Ÿ”ด๐Ÿ”ด
ุนู„ุงุฌุงุช B.blocker ุงุฎุชุตุฑู‡ู… ุงู„ูƒู… ุจ MBC
๐Ÿ”ดMetoprolol succinate
๐Ÿ”ดBisoprolol
๐Ÿ”ดCarvedilol
ุฐู†ูŠ ูู‚ุท ู…ุณู…ูˆุญ ุจูŠู‡ู…
๐Ÿ”ด๐Ÿ”ด
Ivabradine :-
ู‡ุฐุง ุนู„ุงุฌ ูƒู„ุด ู…ู‡ู… ูˆู…ู…ูƒู† ูŠุฌูŠ ุจุฏูˆุฑ ุซุงู†ูŠ
ู‡ุฐุง ูŠุดุชุบู„ ูู‚ุท ุน HR ูŠู‚ู„ู„ HR ู„ุงู† ู‡ูˆ ูŠุดุชุบู„ ุน sinoatrial node
ู ุงู†ุชุจู‡
ุฅุฐุง ูŠุฌูŠ ูƒูŠุณ ุงูˆ ุณุคุงู„ ู…ุจุงุดุฑ ุน ูˆูŠุฑูŠุฏ ุนู„ุงุฌ ู„ู„ HF ูˆูู‚ุท ุน HR ู ู‡ูˆ ุนู„ุงุฌ
Ivabradine
ู‡ุฐุง ุนู„ุงุฌ ูŠุฌูŠ ุจุฏูŠู„ ุนู† B. Blocker
ุจุณ ุดุฑุท ู„ุงุฒู… ุชุณุชุฎุฏู… ุฃุนู„ู‰ ุฌุฑุนุฉ ู…ู† B. Blocker ูˆู…ุง ูุงุฏ ุฃูˆ ุฅุฐุง ูƒุงู† ู…ุฑูŠุถ ู…ุง ูŠูƒุฏุฑ ูŠุณุชุฎุฏู… B. Blocker ุฃูƒุฏุฑ ุงุณุชุฎุฏู… ู‡ุฐุง ุนู„ุงุฌ
๐Ÿ”ด๐Ÿ”ดDigoxin
ู‡ุฐุง ุนู„ุงุฌ ู…ูˆ first line
ูŠู‚ู„ู„ sympathetic activity
ูˆูŠู‚ู„ู„ contractility ุจุงู„ุชุงู„ูŠ ูŠู‚ู„ู„ ู…ู† hospitalization. ูˆุทุจุนุง ู‡ุฐุง ุนู„ุงุฌ ุงุถูŠูู‡ ุจ ูƒู„ุงุณ D
ูˆุงูƒูˆ ู…ุนู„ูˆู…ุฉ ู…ู‡ู…ู‡ ุฌุฏุง ุฌุฏุง

ู‡ุฐุง ุนู„ุงุฌ ูŠุชุญูƒู… ุจ ventricular rate
ุจุณ ู‡ุฐุง ุนู„ุงุฌ ูŠุนุชุจุฑ first line ุฅุฐุง ู…ุฑูŠุถ ุนู†ุฏู‡ ๐Ÿ‘‡

supraventricular arrhythmias
๐Ÿ”ด๐Ÿ”ดVericiguat
ู‡ุฐุง ุนู„ุงุฌ ูŠู†ุธู… contractility ูˆ Diastolic function
ุงู†ุชุจู‡ โ˜๏ธ
ู…ู„ุงุญุธู‡ ุงู„ูŠ ุงุดูˆูู‡ุง ุงู‡ู… ุดูŠ ุจูŠู‡
ู‡ูˆ ุงู„ูŠ ูŠุงุฎุฐูˆู† ู‡ุฐุง ุนู„ุงุฌ ุตุงุฑ ุนุฏู‡ู… anemia
ูˆู‡ุฐุง ุนู„ุงุฌ ู…ุง ูŠุณุชุฎุฏู… ู„ู„ HFpEF
๐Ÿ”ด๐Ÿ”ด๐Ÿ”ดู‡ุณู‡ ู†ุงุฎุฐ ุนู„ุงุฌุงุช HFpEF
ุฐู†ูŠ ุนู„ุงุฌุงุช ูƒ first line
ู‡ูˆ SGLT2 inhibitor

ู‡ุณู‡ ุฑุงุญ ุงุฑุชุจ ุงู„ูƒู… ุงู„ู…ุฎุทุท
ุฅุฐุง ู…ุฑูŠุถ ุนู†ุฏู‡
๐Ÿ”ดHFpEF +fluid retention
ู†ุณุชุฎุฏู… ุงู„ู‡ุง
SGLT2 +loop diuretic

ุฅุฐุง ู…ุฑูŠุถ ุนู†ุฏูŠ
๐Ÿ”ดHFpEF +EF <55-60% +fluid retention
ู†ุณุชุฎุฏู… ุงู„ู‡ุง
SGLT2 inhibitor +MRA (Spironolactone and eplerenone)
ุฅุฐุง ูƒุงู† ู…ุฑูŠุถ ุนู†ุฏู‡
๐Ÿ”ดHFpEF +<55-60%
ู†ุณุชุฎุฏู…
SGLT2 inhibitor +ARNI
ูˆุงุฐุง ูƒุงู† ุบุงู„ูŠ ุน ู…ุฑูŠุถ ุงุณุชุฎุฏู… ุฅู„ู‡ ARB ุจุฏู„ ARNI
#hf ๐Ÿ‘†๐Ÿซ€
โšœ๏ธARNIโšœ๏ธ

The most common adverse effects include :
hypotension, dizziness,
hyperkalemia, worsening renal function, and cough. โš ๏ธAngioedema is most common with sacubitril/valsartan than with enalapril.
โ›”๏ธโš ๏ธSacubitril/valsartan is contraindicated in patients with a history of angioedema associated with an ACE inhibitor or ARB.


โ›”๏ธโš ๏ธIt is also contraindicated in pregnancy๐Ÿคฐ๐Ÿปand should not be used
concurrently with ACE inhibitors or other ARBs.
โ‡๏ธ๐Ÿ’ŠCarvedilol, metoprolol succinate (CR/XL), and bisoprolol are the only
ฮฒ-blockers shown to reduce mortality in large HF trials.
โš ๏ธโ›”๏ธAvoid aldosterone antagonists in patients with renal impairment, elevated serum potassium, or history of severe hyperkalemia.
โ‡๏ธโ‡๏ธSpironolactone also interacts with androgen and progesterone
receptors, which may lead to gynecomastia, impotence, and
menstrual irregularities in some patients.
๐Ÿ”ฐIsosorbide dinitrate (ISDN) is a venodilator that reduces preload, whereas hydralazine is a direct arterial vasodilator that reduces systemic vascular resistance (SVR) and increases stroke
volume and CO.
๐Ÿ‘ฑ๐Ÿฟโ€โ™‚๏ธ๐Ÿ‘ฉ๐Ÿฟโ€๐ŸฆฐGuidelines recommend addition of hydralazine/ISDN to black
patients with HFrEF who are receiving optimal medical therapy.
๐Ÿ’Š๐ŸŒฟDigoxin may also be considered to help control ventricular rate
in patients with HFrEF and supraventricular arrhythmias.
โญ•๏ธThe drug was well tolerated overall, but there was an unexplained greater incidence of anemia in patients treated with vericiguat.
๐Ÿซ€๐Ÿ’ŠVericiguat may be considered in addition to optimized HF
therapy to reduce morbidity and mortality in patients at high risk
with worsening HFrEF.

#hf
โ™ฆ๏ธู…ูู„ุฎุต ูˆู…ู„ุงุญุธุงุช ู…ู‡ู…ุฉ ุนู† HF ๐Ÿฆฆ๐ŸŒš


๐Ÿ”†ู…ุณุจุจุงุช ุงู„ู€HF ู‡ู… coronary artery disease ูˆุงู„ู€ hypertension ๐Ÿ”ซ๐Ÿ—ฟ

๐Ÿ”†ุชุดุฎูŠุต ventricular hypertrophy ูŠูƒูˆู† ุนู† ุทุฑูŠู‚ chest radiograph ูˆุงู„ู€ ECG๐Ÿ“ˆโ™ฅ๏ธ

๐Ÿ”†ูˆุงุฐุง ุฑุฏู†ุง ู†ุญุฏุฏ ุงู„ู€ dysfunction ู…ุงู„ systolic ูˆ diastolic ู†ุณุชุฎุฏู… Echocardiogram โค๏ธ๐ŸŒš

๐Ÿ”†ูƒูŠ ู„ุง ู†ู†ุณู‰ ุงู„ู€ first line agent ุจู€HFrEF

๐Ÿ’ ACEi,ARBs,ARNI
๐Ÿ’ B blockers
๐Ÿ’ SGLT2 inhibitor
๐Ÿ’ aldosterone antagonist

๐Ÿ”†ู†ูุถู„ ุงู„ู€ thiazides ุนู„ู‰ loop diuretic ุจุญุงู„ุฉ ูˆุญุฏุฉ ุงุฐุง ุฌุงู† ู…ุฑูŠุถ ุนู†ุฏู‡ mild fluid retention ูˆBP ู…ุงู„ุชู‡ ุนุงู„ูŠ ๐Ÿฅฒ๐Ÿ’”

๐Ÿ”†ู„ุงุฒู… ุชุชุฐูƒุฑ ูƒู„ ู…ุฑุถู‰ HFrEF ู„ุงุฒู… ูŠุงุฎุฐูˆู† ACEi ุญุชู‰ ู„ูˆ ู…ุฌุงู† ุนุฏู‡ู… ุงุนุฑุงุถ ุนู„ู…ูˆุฏ ู†ู‚ู„ู„ morbidity ูˆ mortality ๐Ÿ’˜๐Ÿงธ

๐Ÿ”†ุงู„ุงุฏูˆูŠุฉ ุงู„ุซู„ุงุซุฉ ู…ู† ู…ุฌู…ูˆุนุฉ ARBs ุงู„ูŠ ู†ุณุชุฎุฏู…ู‡ู… ู‡ู…

๐Ÿ’ฎcandesartan
๐Ÿ’ฎvalsartan
๐Ÿ’ฎlosartan

๐Ÿ”†ุงู„ู…ุฑุถู‰ ุงู„ูŠ ุนุฏู‡ู… HFrEF ู†ูุถู„ ู†ุณุชุฎุฏู…ู„ู‡ู… ARNI ุนู„ู‰ ARBs ูˆACEi ู„ุงู† ู…ู…ูƒู† ูŠุณูˆูˆู† improve survival ๐Ÿ˜ตโ€๐Ÿ’ซ๐Ÿ’”


๐Ÿ”†ุงู„ู…ุฑูŠุถ ุงู„ูŠ ูŠุงุฎุฐ ACEi ุงูˆ ARBs ูˆู†ุฑูŠุฏ ู†ุญูˆู„ู‡ ู„ู„ู€ ARNI ู„ุงุฒู… ุงูƒูˆ ุดุฑูˆุท

๐Ÿ‘จโ€๐Ÿฆณุงู„ุญุฌูŠ ุงู„ูŠ ูŠุงุฎุฐ ACEi ู„ุงุฒู… ูŠูˆูƒูู‡ 36 ุณุงุนุฉ ู‚ุจู„ ู„ุง ูŠุจู„ุด ุจู€ ARN ๐Ÿ˜žโœจ

๐Ÿง‘โ€๐Ÿฆณูˆุงู„ุญุฌูŠุฉ ุงู„ูŠ ุชุงุฎุฐ ARBs ุนุงุฏูŠ ุชูƒุฏุฑ ุชูˆูƒูู‡ ู…ู† ู‡ู†ุง ูˆุชุจู„ุด ุจู€ARNI ู…ู† ู‡ู†ุง ๐Ÿฆฆ๐Ÿ’”

๐Ÿ”†ุจุงู„ู†ุณุจุฉ ู„ู„ู€angioedema ุชุตูŠุฑ ูˆูŠุง ุงู„ู€ARNI ุงูƒุซุฑ ู…ู† enalpril ู†ูุณู‡ ๐ŸŒš๐Ÿ’”

๐Ÿ”†ุงุณุชุฎุฏุงู… ุงู„ู€B blockers ู„ูƒู„ ุงู„ู…ุฑุถู‰ ุงู„ูŠ ุญุงู„ุชู‡ู… stable HFrEF ุจุณ ู…ู…ู†ูˆุน ู†ู†ุทูŠู‡ุง ุจู€Acut๐ŸฆฆโŒ

๐Ÿ”†ูˆุญุฏุฉ ู…ู† ุงู‡ู… ุงู„ุงุนุฑุงุถ ุงู„ุฌุงู†ุจูŠุฉ ู„ู„ู€ vericiguat ุชุณูˆูŠ anemia๐Ÿฉธ๐Ÿงผูˆู‡ู… ู…ุง ุชุณุชุฎุฏู… ุจู€HFpRF


๐Ÿ”†ูƒู„ ุงู„ู…ุฑุถู‰ ุงู„ูŠ ุนุฏู‡ู…HFpEF ู„ุงุฒู… ู†ุจุฏูŠ ูˆูŠุงู‡ู… ุจู€SGLT2i ูˆุงู„ุจุงู‚ูŠ ู†ู†ุทูŠู‡ู… ุญุณุจ ุงู„ุญุงู„ุฉ ๐Ÿฆฆ๐Ÿคทโ€โ™‚๏ธ

๐Ÿ”†ุจุญุงู„ุฉ diuretic resistance ู†ู†ุทูŠู‡ุง ุจุดูƒู„ iv infusion ุงูˆ ู†ู†ุทูŠ diuretic ุจู…ูŠูƒุงู†ุฒู… ูŠุฎุชู„ู ุนู† loop diuretic โ™ป๏ธโ™ฟ๏ธ

ู‡ุงูŠ ุงู‡ู… ุงู„ุดุบู„ุงุช ุงู„ู…ูˆุฌูˆุฏุฉ ุจู€ HF ูˆุงุบู„ุจ ุงู„ุงุณุฆู„ุฉ ุชุฌูŠ ู…ู†ู‡ุง โšก๏ธ๐Ÿค–

๐Ÿ”ุงูŠ ุทุงู„ุจ ู…ุง ูŠุญูุธ ู‡ุฐุง ุงู„ู…ู„ุฎุต ุฑุงุญ ุชููˆุชู‡ 7MCQs ุนู„ู‰ ุงู„ุงู‚ู„ ู…ูŠุฌุงูˆุจู‡ุง ๐Ÿ˜๐Ÿ’ฏ
#hf
Note ๐Ÿ“

๐Ÿ“Œุฌุงุจุชุฑ DM part 2 ุณุฑูŠุฑูŠู‡ ุฑุงุจุนู‡

ู‡ุฐุง ุงู„ุจุงุฑุช ุงูƒุซุฑ ุดูŠ ุจุณ ุงู„ุงุณุฆู„ู‡ ุงู„ูŠ ุชุฌูŠ ุนู„ู‰ ุดูƒู„ ูƒูŠุณุงุช ู ุฑุงุญ ุงูƒุชุจู‡ ุจ ู‡ุงุงูŠ ุทุฑูŠู‚ู‡ ูˆ ุงู„ูƒู„ุงู… ุงู„ู…ู‡ู… ูˆ ุงู„ุญูุธ ุงุฏุฒู‡ู† ุตูˆุฑ โœจุŒุŒ

ุนู„ุงุฌุงุช type 2
-
ุฅุฐุง ุงู„ุณุคุงู„ ุฌุงู† ู…ุฑูŠุถ ู…ุง ุนู†ุฏู‡ ุงูŠ ู…ุถุงุนูุงุช ุจุณ DM 2 ู†ู†ุทูŠ metformin

-ุงุฐุง ุงู„ุณุคุงู„ ุฌุงู† ู…ุฑูŠุถ ุนู†ุฏู‡ A1C ุงู‚ู„ ู…ู† 7.5 ู†ู†ุทูŠ metformin +life stayle

-ุฅุฐุง ุงู„ุณุคุงู„ ุฌุงู† ุงู„ู…ุฑูŠุถ ุนู†ุฏู‡ A1C ุงูƒุซุฑ ู…ู† 1.5 ู†ู†ุทูŠ metformin +second line

-ุฅุฐุง ุงู„ุณุคุงู„ ุฌุงู† ุงู„ู…ุฑูŠุถ ุนู†ุฏู‡ A1C ุงูƒุซุฑ ู…ู† 10 ู†ู†ุทูŠ insulin ูˆ ูŠูุถู„ GLP1-RA
#diabetes
ุงุฏูˆูŠู‡ ุงู„ุฌุฒุก ุงู„ุฃูˆู„ ูู‚ุท ุงู„ุฃุดูŠุงุก ุงู„ู…ู‡ู…ู‡ ูˆุฒุงุฑูŠุง ุฌู†ุช ูƒุงุชุจู‡ุง ู„ูŠูˆู… ุงู„ุงู…ุชุญุงู†




โค๏ธโค๏ธู„ู…ูŠุชููˆุฑู…ูŠู† ู…ู†
ุนุงุฆู„ู‡ Biguanides
ูŠููŠุฏ ู„ู„ุฏู‡ูˆู† ูŠุฎูุถ ุฏู‡ูˆู† ุซู„ุงุซูŠู‡ ูˆุถุงุฑู‡ ูˆูŠุฒูŠุฏ ุฏู‡ูˆู† ู†ุงูุนู‡

ู…ุง ูŠุฎูุถ ุณูƒุฑ ูู‚ุท ูŠุฎูุถ ูˆุฒู† ู…ู† 1_2

ู„ู…ูŠุชููˆุฑู…ูŠู† ูŠุณุจุจ ู†ู‚ุต
B12)((Cobalamin))


ูŠุณุจุจ ุงุถุทุฑุงุจ ุจ GIT
ู„ู‡ุฐู‡ ู†ุตู†ุนู‡ Extended release
ูˆุชุงุฎุฐู‡ ู…ุน ุงู„ุงูƒู„ ุงูˆ ูˆุฑุง ู„ุงูƒู„ ู…ุจุงุดุฑ

ู…ูŠุณูˆูŠ lactic acidosis

ูŠุฎุฑุฌ ุนู†ุฏ ุทุฑูŠู‚ ุงู„ูŠูˆุฑู†
ูŠุชุฑุงูƒู… ุจุงู„ูƒู„ู‰ ุจุญุงู„ู‡ ุงู„ู‚ุตูˆุฑ ูˆุงุฐุง ุฑุฏู†ู‡ ู†ุณูˆูŠ lV dye ู†ุชูˆู‚ู 2_3 ุงูŠุงู…
ู†ุณุชุฎุฏู…ู‡ ูƒูˆู…ุจู†ูŠุดู† ู…ุน TZDs

ู…ู†ูˆ ูŠุณุชุฎุฏู… ู„ุชูƒูŠุณ ุงู„ู…ุจุงูŠุถุŸ
Polycystic Ovary Syndrome
ุงู„ุงุฎุชุตุงุฑ: PCOS
ู…ูŠุชููˆุฑูŠู†



โค๏ธโค๏ธุณู„ูุงู†ูŠู„ูŠูˆุฑูŠุง 1-glyburide
2-glipizide
3-glimepiride
ูƒู„ุด ุฒูŠู†ู‡ ูˆูุนุงู„ู‡ ูˆุฑุฎูŠุตู‡ ู…ู…ูƒู† ุชุณุจุจ ู‚ู„ูŠู„ ู…ู† ุชุญุณุณ ุณู„ูุฑ
ุจุณ ู‡ูŠ ุฎุทุฑู‡ ุชุฎูุถ ุณูƒุฑ ูˆ ุชุฒูŠุฏ ูˆุฒู†

ูˆุงู„ู…ุฑูŠุถ ูŠุตูŠุฑ ุนู†ุฏู‡ tachyphylaxis ูŠุนู†ูŠ ูŠุชุนูˆุฏ ุนู„ูŠู‡ ุจุนุฏ ู…ุง ูŠุดุชุบู„
ุฎุงู ูŠูƒูˆู„ูˆู† ู…ู†ูˆ ุฃุดู‡ุฑ ุณุงูŠุฏ ุงููŠูƒุช ู‡ู„ ุนุงุฆู„ู‡ ู†ูƒุชุจ ุฒูŠุงุฏู‡ ูˆุฒู† 1_2



โค๏ธโค๏ธThiazolidinedione (TZD)
ูŠุดุชุบู„ ุน ุฑุณุจุชุฑ PPAR

ู…ุง ูŠู†ุทูˆู† ูุนุงู„ูŠู‡ ุงู„ุง ูˆุฑุง 3_4 ุงุดู‡ุฑ ูˆู…ุง ูŠุนุชุจุฑูˆู† ุฎุท ุนู„ุงุฌูŠ ุงูˆู„ ู„ุงู† ู…ูˆุฒูŠู†ุงุช
ูƒู„ู†ู‡ ู†ุฎู„ุทู‡ู… ูˆูŠ ู…ูŠุชููˆุฑู…ูŠู† ู„ุนู„ุงุฌ ู†ูˆุน ุซุงู†ูŠ
ูˆูƒู„ู†ู‡ ู…ูˆุฒูŠู†ุงุช ู„ูŠุดุŸ ู„ุงู† ูŠุณุจุจู† ูˆุฐู…ู‡ ูˆุงุญุชุจุงุณ ุณูˆุงุฆู„ ูุดู„ ู‚ู„ุจ ูŠุชูุงู‚ู… ูˆุชุฎููŠู ู‡ูŠู…ูˆูƒู„ูˆุจูŠู† ูˆู‡ูŠู…ุงุชูˆูƒุฑูŠุช ูˆุฒูŠุงุฏู‡ ูˆุฒู†
ู…ู…ู†ูˆุน ู…ู†ุนุง ุจุงุชุง ูุดู„ ู‚ู„ุจ ู†ูˆุน lll ูˆlV

ู†ุณุชุฎุฏู…ู‡ ุจุญุฐุฑ ูุดู„ ู‚ู„ุจ ll ูˆ l
ูŠุณุจุจู† ุฒูŠุงุฏู‡ ูˆุฒู† ุจุณุจุจ ุงู„ุณูˆุงุฆู„ ูˆุงู„ูˆุฐู…ู‡

โค๏ธโค๏ธGlP1_RAs

1_Dulaglutife
2_lixisenatide
3__liraglutid
4_Semaglutide
5_exenatide
6_exenatide xR

ฺฏู„ุจ ู…ุตุทู„ุญ ฺฏู„ุจ ุณูŠู…ุง ูˆุงุฎุชู‡ุง ุงูƒุณู†ุงุช ุนุฏู‡ู† ู„ูŠุฑุง ูู„ูˆุณ ุงุดุชุฑุช ู„ูƒุฒุฒ๐Ÿ˜”๐Ÿ“


ูŠุญุณุณู† ู„ู…ุฑูŠุถ ุจุงู„ุดุจุน ูˆูŠุจุทุฆูˆู† ุงูุฑุงุบ ุงู„ู…ุนุฏู‡ ูŠุฎูุถ ูˆุฒู† ู‡ุฐู† ูŠุณุชุฎุฏู…ูˆู†ู‡ ู„ู„ุชู†ุญูŠู ุชู‚ู„ู„ ูˆุฒู† ู…ู† 1_2


ู‚ุตูŠุฑุงุช ุงู„ู…ูุนูˆู„ lixisenatide/exenatide


ุทูˆูŠู„ุงุช ุงู„ู…ูุนูˆู„
Dulaglutife
Semaglutide
exenatide xR
Liraglutide

ูŠุดุชุบู„ู† ุน FPGูˆ PPG
ูุนุงู„ ุงูƒุซุฑ
FPG

ู‡ุฐู‡ ู…ู‡ู…ู‡FAD ุงุจุฑูˆู ูˆุตุช ุจ
Dulaglutide /Liraglutide /Semaglutid
ู„ุงู† ูŠู‚ู„ู„ู† ุฎุทุฑ ุงู„ู‚ู„ุจ ูˆ ุงู„ุงูˆุนูŠู‡ ุจุณูƒุฑ ู†ูˆุน ุซุงู†ูŠ


ู‡ุฐู† ู†ุณุชุฎุฏู…ู‡ู… ูƒ ุนู„ุงุฌ ูุฑุฏูŠ ู…ูˆู†ูˆุซุฑุจูŠโœจ
ูˆู‡ุฐู† ุณุชุชู‡ู… ู…ุชูˆูุฑุงุช ูƒ ุงุจุฑ ุชุญุช ู„ุฌู„ุฏ


ูู‚ุท Semaglutid ู…ุชูˆูุฑ ุงุจุฑู‡ ูˆูู…ูˆูŠ

โค๏ธโค๏ธDPPุนุงุฆู„ู‡
Alogliptin, linagliptin, saxagliptin, and sitagliptin

ุฌู„ุจุช
ู…ุตุทู„ุญ ุนุงุฆู„ู‡ ุฌู„ุจุช ู‡ูŠ ู„ูŠู†ุง ุฌุงู„ุณู‡ ุณุงุฏุณ ูˆุญุฏู‡ ูˆุชุฎุงุจุฑ๐Ÿ˜”๐Ÿ“


ุทูˆูŠู„ ู…ูุนูˆู„ ู…ุฑู‡ ูˆุญุฏู‡

ุชู†ู‚ุต ุณูƒุฑ ุจุฏูˆู† ู…ุง ุชุฎูุถ ุณูƒุฑ ุจู†ุณุจู‡ ูƒุจูŠุฑู‡

ู†ุทูŠู‡ู… ูƒ ุนู„ุงุฌ ู…ูุฑุฏโœจ ูŠุนุชุจุฑ ุฎุท ุนู„ุงุฌูŠ ุซุงู†ูŠ ู„ูˆ ุซุงู„ุซ
ู„ูˆุฒู† ูŠุจู‚ู‡ ู…ุนุชุฏู„

โค๏ธโค๏ธSGLT_2
Canagliflozin
dapagliflozin
empagliflozin, and
ertugliflozin

ุฌู…ุงุนู‡ ุณูƒู„ูˆุช ุซุงู†ูŠ ู‡ู† ุนุงุฆู„ู‡ ูู„ูˆุฒูˆู†
ูŠุฑูˆุญ ูŠู…ู†ุน ู†ุงู‚ู„ ู…ูˆุฌูˆุฏ ุจุงู„ูƒู„ุฆ

ุงูƒุฏุฑ ุงุถูŠู ูˆูŠุงู‡ู† ู„ู…ูŠุชููˆุฑู…ูŠู†
ุงูˆ ุงูŠ ุนู„ุงุฌ ุฎุท ุซุงู†ูŠ
ุงูƒุฏุฑ ุงุฎุฏู‡ ู„ูˆุญุฏุฉ ุงุฐุง ุงู„ู…ุฑูŠุถ ู…ุง ูƒุฏุฑ ูŠุชุญู…ู„ ุงุซู†ูŠู† ูˆุงุฐุง ู„ู…ุฑูŠุถ ู…ุง ูŠูƒุฏุฑ ูŠุงุฎุฐ ู…ูŠุชููˆุฑู…ูŠู†


ู…ู‡ู… ุงูƒุฏุฑ ุงูˆุตูŠ ุจูŠู‡ ู„ู„ู…ุฑุถุฆ
Hf
CKD
ASCVD

ู…ุง ุงุชุณุจุจ ู†ู‚ุต ุณูƒุฑ ุงู„ุง ุจุญุงู„ ุฏู…ุฌู†ุงู‡ุง ูˆูŠ ุนุงุฆู„ู‡ ุณู„ูุงู†ุง ูˆุงู„ุงู†ุณูˆู„ูŠู† ูˆุงู„ู…ูŠูƒู„ู†ุชูŠุฏ


ู…ู‡ู… ู…ู‡ู…
genital mycotic infections,
ุฃูƒุซุฑ ุณุงูŠุฏ ุงููŠูƒุช ู‡ูˆู‡ ุงู„ุชู‡ุงุจ ู…ุฌุงุฑูŠ ุจูˆู„ูŠู‡ ุจุงู„ู†ุณุงุก ูˆูƒุซุฑู‡ ุชุจูˆู„ ูˆุฌูุงู ูˆุฏูˆุงุฑ ูˆุงู†ุฎูุงุถ ุถุบุท ุจุณุจุจ ุชุงุซูŠุฑ ุชู†ุงุถุญ
#diabetes
Type 1 ุนู„ุงุฌุงุช
-ุงูŠ ุณุคุงู„ ุงู„ู…ุฑูŠุถ ู„ุงุฒู… ูŠุงุฎุฐ ุฃู†ุณูˆู„ูŠู† ูˆ ูŠูƒูˆู† combination Basel and bolus ู„ุงุฒู… ูŠูƒูˆู† 50% ุจ 50%

-ู„ุงุฒู… ุงู„ู…ุฑูŠุถ ุงู„ูŠ ูŠุตูŠุฑ ุนู†ุฏู‡ ู‡ุฐู†ูŠ ุงู„ุญุงู„ุชูŠู† ุงูŠุณูˆูŠ CGM ( ู…ุฑุงู‚ุจู‡ ู…ุณุชู…ุฑู‡ ู„ู„ุณูƒุฑ ) :

*ุฏุงุฆู…ุง ูŠุตูŠุฑ ุนู†ุฏู‡ hypoglycaemia
*ูˆ ุงู„ู…ุฑูŠุถ ุงู„ูŠ ูŠุงุฎุฐ ุงู„ุนู„ุงุฌ ูˆ ู…ุง ุญู‚ู‚ ุงู„ู‡ุฏู ู…ู† ุงู„ุนู„ุงุฌ ุงู„ูŠ ู‡ูˆ A1C ูŠูƒูˆู† ุงู‚ู„ ู…ู† 6.5

-ู„ุงุฒู… ุงู„ู…ุฑูŠุถ ุงู„ูŠ ู…ุง ู…ุณูŠุทุฑ ุนู„ู‰ ุงู„ุณูƒุฑ ูŠุณูˆูŠ ู…ุฑุงุฌุนู‡ ูƒู„ 3 ุงุดู‡ุฑ
ูˆ ุงู„ู…ุฑูŠุถ ุงู„ูŠ ู…ุณูŠุทุฑ ุนู„ู‰ ุณูƒุฑ ูŠุณูˆูŠ ู…ุฑุงุฌุนู‡ ูƒู„ 6 ุงุดู‡ุฑ
ุชุงุจุนู‡ ู„ู„ Type 1
#diabetes